Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

Aug 23 2019

• By Joseph Haas and Alexandra Shimmings

DealWatch_1200x675

Related Content

Genexine, ToolGen Merger Collapses Amid Stock Drops, But Collaboration Still Planned

Aug 22 2019

Bayer Says $7.6bn Farewell To Animal Health As It Sells Unit To Elanco

Aug 21 2019

Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines

Mar 07 2018

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

Jun 07 2019

Defusing US Opioid Crisis Offers Orexo "Strong Growth Potential" Says CEO

Apr 10 2019

Advanz Has Six Deals In The Works As It Cuts Its Losses

Aug 16 2019

Alvogen Advances Its Branded Offering Via Agreements

Aug 21 2019

Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation

Aug 16 2019

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Nov 15 2018

Related Companies

Merck & Co., Inc.

Themis Bioscience GmbH

Institut Pasteur

Innovent Biologics, Inc.

Eli Lilly and Company

AstraZeneca PLC

Iconic Therapeutics, Inc.

Orexo AB

Bausch Health Companies Inc.

LEO Pharma A/S

Kyowa Kirin Co., Ltd.

Lupin Limited

Genexine Inc.

Bayer AG

Monsanto Company

Covis Pharma B.V.

Alvogen, Inc.

ADVANZ PHARMA Corp. Limited

Glenmark Pharmaceuticals Limited

Genentech, Inc.

Additional Topics

Deals Business Strategies M & A Commercial BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window